Leiomyosarcoma, liver metastasis, Roux-en-Y gastric bypass surgery
Silva NA, Santos LAM, Santos VM. Metastatic leiomyosarcoma of the excluded stomach: a case report. J Gastric Surg 2020; 2(3): 98-101
Received: August 7, 2020
Accepted: August 29, 2020
Article in press: August 30, 2020
Published online: August 31, 2020
Prof. Dr. Vitorino Modesto dos Santos, MD, PhD
Armed Forces Hospital
Estrada do Contorno do Bosque s/n, Cruzeiro Novo
70658-900, Brasília-DF, Brazil.
vitorinomodesto@gmail.com
Telephone: + 55-61 3966210
Leiomyosarcoma (LMS) represents about 1% of primary malignancies of the stomach, evolves with hepatic implants in 2-thirds of cases, and the outcome is often poor [1-7]. Immunosuppression, Epstein-Barr virus, chemicals, and radiation can be related factors [2,6]. Spindle cells of the muscularis propria or muscularis mucosa present high proliferation rates and positivity for desmin, a–muscle-specific actin, and vimentin [2,3,6]. Although immunohistochemical findings can avoid pitfalls with other gastrointestinal tumors, the diagnosis often occurs at late stages because of the insidious clinical course [2-7]. LMS predominantly affects female adults (5:3) and the sixth decade of life, pain occurs in near 75% of patients and the control is very difficult in the majority of them [1,2]. Bleeding, weight loss, and gastroesophageal reflux are other frequent symptoms [2-4]. Whenever possible, surgical resection is the effective treatment; otherwise, palliative care and repeated hepatectomy for metastasis resection may prolong the survival rate in some cases [1-5]. Recurrences after resections and distant metastases may develop in up to 50% of patients [5]. Anthracycline-based chemotherapy, ifosfamide, gemcitabine, docetaxel, trabectedin, and pazopanib constitute additional therapeutic options, with variable response rates [6,7]. Because of the exceeding rarity, case reports can increase the understanding of gastric LMS.
A 53-year-old Caucasian male who underwent a Roux-en-Y gastric bypass (RYGB) in 2005 due to grade III obesity, and laparoscopic cholecystectomy in 2006, was admitted in 2018 claiming of abdominal pain since seven days ago. He denied weight loss, nausea, vomiting, and digestive hemorrhage; and reported being a former smoker (five packs/year). There was no antecedent of Epstein-Barr virus infection, Wilms tumor, or immunosuppression. On physical examination, his BMI was 39.20 kg/m², with normal vital signs and unremarkable abdomen evaluation. The results of routine laboratory tests were normal. The computed tomography (CT) of the abdomen (
Considering the strong hypothesis of a metastatic gastrointestinal stromal tumor (GIST) from the excluded stomach, the patient initially underwent a schedule with imatinib (400 mg/day) from July 2018 to June 2019. Although the disease seemed stable with this therapy, the patient underwent another biopsy of the mass in the excluded stomach guided by ultrasound. The immunohistochemical panel showed vimentin V9 and actin 1A4 positive, while CD117 (c-kit), CD34, and S100 protein were negative. These data confirmed the diagnosis of leiomyosarcoma in an excluded stomach. Then, the chemotherapy changed by liposomal doxorubicin (75 mg/m²) from July till October 2019. Since December he is utilizing docetaxel in association with gemcitabine. The latest control imaging revealed the stability of the hepatic implants, bone lesions, and pulmonary nodules; however, the disease progressed affecting the central nervous system. Currently, the patient is clinically stable under follow-up care by the service of radiotherapy.
The male patient herein described underwent bariatric surgery for the management of his obesity. The RYGB procedure resulted in a reduction of his gastric volume by defining a small proximal gastric pouch without the remaining stomach [8]. This postoperative anatomy change corresponds to the called “excluded stomach” from the gastrointestinal tract. And the persistent alkaline effect of duodenal bile reflux has been related to the gastric cancer risk [8]. Excluded stomachs can harbor a great number of bacteria and fungi, with a variable degree of gastritis, atrophy, and intestinal metaplasia which may predispose to gastric malignancy [8]. An additional concern might be the finding of 5-ciprinol sulphate, a toxic bile alcohol present in certain dysfunctional conditions, including inflammation and hepatic carcinogenesis [8]. Notwithstanding, with respect specifically to gastrointestinal LMS, the known predisposing factors include a history of Wilms tumor, immunosuppression, and EBV infection [2]. Worthy of note in this setting is the underestimated diagnosis of malignancy in the excluded stomach because of the difficult endoscopic evaluation of this special anatomical region [8]. Concordant with literature, the patient was in the sixth decade of life, had an insidious clinical course with no-specific abdominal pain, and presented with liver metastasis at diagnosis. And his poor outcome included recent implants in bones, lungs, and the central nervous system. There was no remarkable response of distant metastases to the chemotherapy schedules [6]. Because of the development of brain implants, he was referred to treatment by radiotherapy. Although the results of this therapy are usually poor, that is also a resource utilized in LMS. The first hypothesis of GIST was ruled out by CD117 (c-kit) and CD34 negativity, while the positivity of vimentin V9 and actin 1A4 were consistent with the diagnosis of gastric LMS. Except for the previous RYGB, there was no significant risk factor for gastric malignancy [8]. Late diagnosis and misdiagnosis of gastrointestinal LMS with GISTS are frequent, as well as multiple metastases at diagnosis, unsatisfactory therapeutic responses, and poor outcomes. Cheng et al. reported a 43-year-old woman with a previous resection by Billroth I procedure of a gastric tumor (3cm) 1 year ago [1]. Symptoms were weakness and abdominal discomfort. The initial diagnosis was a spindle cell tumor and she had no postoperative adjuvant therapy. Histological, immunohistochemical and genetic evaluations done by authors showed a LMS. The results were SMA (+), calponin (+), CD34 (-); CD117 (-), DOG (-), desmin (doubtful), S-100 (-), Ki-67 (15%+); and no KIT exon 9, 11, 13, 17, or PDGFRA exon 12 or 18 mutation. The patient claimed of low back pain, had severe anemia, liver, and lymph node metastases. She underwent transarterial chemoembolization with oxaliplatin and tetrahydropalmatine emulsion with lipiodol, plus high-intensity focused ultrasound for retroperitoneal metastases. The choice of this alternative management was due to her fragile clinical general status [1].
Gubatan and Shah reported a 50-year-old man with the antecedent of Wilms tumor and presenting with gastrointestinal bleeding by a percutaneous endoscopic gastrostomy tube [2]. The endoscopy showed a large ulcerated mass on the gastric body. The immunohistochemical study was consistent with LMS [positive for cytokeratin, calponin, actin, and desmin (focal); and negative for CD117, S100, CK5/6, Cam5.2, ALK-1, CD34, CD31, and myogenin]. The patient and his family decided against any kind of therapy because of his poor prognosis [2]. Hasnaoui
Mehta
The evolution of our patient corresponds to descriptions of other cases of this malignancy. The diagnosis of gastric LMS often occurs at late stages because of the insidious clinical course. The rate of liver metastasis at diagnosis is high. Besides, the relatively poor response to the alternative management for non-surgical stages of the disease yields severe outcomes. Close control of the excluded stomach is necessary after RYGB due to the risk of malignancy.
None
NAS, LAMDS, VMDS conceptualized and designed the study, acquired, and analyzed data, interpreted the study results, drafted the manuscript, and critically revised the final version of the manuscript.
No funding was received for this study.
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Further information is available from the corresponding author on reasonable request.
Not applicable.
Not commissioned; externally peer reviewed.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non- Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/